Abstract:In cirrhosis, the detoxification ability of ammonia produced during protein metabolism is reduced, and the arterial blood ammonia concentration is higher than the venous blood ammonia concentration, leading to a decrease in the branched‐chain amino acids to tyrosine ratio. Ammonia is thought to have a crucial role in the pathogenesis of various complications of cirrhosis, including hepatic encephalopathy, sarcopenia, liver fibrosis, immunodeficiency, and others. Even during periods when the venous blood ammonia concentration is within the normal range in cirrhosis, abnormal ammonia metabolism within the body is considered if the branched‐chain amino acids to tyrosine ratio is low, leading to the concept of the latency period of abnormal ammonia metabolism. Ammonia plays a crucial role in the pathogenesis of hepatic encephalopathy. Ammonia is also involved in many other pathological conditions seen in cirrhosis, such as sarcopenia, liver fibrosis, hepatocellular injury, immune dysfunction, and hyperammonemia. Furthermore, the ammonia level of the veins is a useful prognostic factor for cirrhosis. In cirrhosis without hyperammonemia of the vein, however, covert hepatic encephalopathy has been reported. This discrepancy is because of the anatomical features of ammonia metabolism. There are two systems in the body for detoxifying ammonia: one is the urea cycle in the liver, and the other is the glutamine synthesis pathway in skeletal muscle and other tissues. The blood processed in the liver's urea cycle is then transported via arteries to various organs. Further processing occurs in the brain and skeletal muscle's glutamine synthesis pathway before entering the veins. When the urea cycle function decreases in cirrhosis, the ammonia levels in the artery increase. In response, the glutamine synthesis pathway compensates by increasing the capacity to process ammonia. Therefore, the ammonia concentration in the veins downstream of skeletal muscles does not increase immediately. However, the brain and skeletal muscles, which receive arterial blood, might be exposed to high ammonia concentrations. In addition, branched‐chain amino acids in venous blood decrease. This period is the transition phase from early‐ to late‐phase cirrhosis, and understanding the pathophysiology during this stage is extremely important for preventing the progression of cirrhosis.

Down the road towards hepatic encephalopathy. Urea synthesis - the liver workhorse of nitrogen metabolism

Down the road towards hepatic encephalopathy. The elusive ammonia– what determines the arterial concentration?

Ammonia in liver diseases: A glimpse into the controversies and consensus

Hepatic encephalopathy as a result of ammonia-induced increase in GABAergic tone with secondary reduced brain energy metabolism

Hyperammonemia in Hepatic Encephalopathy

Mitochondrial targets in hyperammonemia: Addressing urea cycle function to improve drug therapies

Role of ammonia in NAFLD: An unusual suspect

Ammonia-induced stress response in liver disease progression and hepatic encephalopathy

Navigating the Gut-brain Axis: Insights into the Pathogenesis of Hepatic Encephalopathy

Inborn Defects of the Mitochondrial Portion of the Urea Cycle a

Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so‐called latency period of abnormal ammonia metabolism

Pivotal role of glutamine synthetase in ammonia detoxification

Impaired Enzymatic Antioxidant Defense in Erythrocytes of Rats with Ammonia-Induced Encephalopathy: Role of NMDA Receptors

NMDA Receptors and Indices of Energy Metabolism in Erythrocytes: Missing Link to the Assessment of Efficiency of Oxygen Transport in Hepatic Encephalopathy

Quo vadis ureagenesis disorders? A journey from 90 years ago into the future

Clinical findings of patients with hyperammonemia affected by urea cycle disorders with hepatic encephalopathy

Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis

Hyperammonemia Enhances the Function and Expression of P‐glycoprotein and Mrp2 at the Blood–brain Barrier Through NF‐κB

Effects of hyperammonaemia on brain function

Hepatic Encephalopathy Is Not Always due to Liver Cirrhosis

Hyperammonaemia: review of the pathophysiology, aetiology and investigation